Last updated on October 2018

Study of Ibrutinib and Rituximab in Treatment Na ve Follicular Lymphoma

Brief description of study

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment nave subjects with follicular lymphoma.

Clinical Study Identifier: NCT02947347

Contact Investigators or Research Sites near you

Start Over

Silvie Aarts

Fakultni nemocnice Hradec Kralove
Hradec Kralove, Czechia
  Connect »